Abstract:Recent studies showed that stereotactic ablative radiotherapy may provide survival benefit for cancer patients with a limited number of metastases lesions treated with curative intent. We hypothesized that stereotactic ablative radiotherapy is safe and effective in tumor control due to its ablative dose and high accuracy of irradiation. In this study we investigate the safety and efficacy of this treatment for patients with oligometastases from colorectal cancer (CRC). Forty-five histologically confirmed colorectal cancer patients were recruited from September 2017 to August 2019. The median age was 60 years and 12 patients were women. Each patient was treated with stereotactic ablative radiotherapy for one oligometastatic lesion unsuitable for resection or standard therapies. Among them 25 patients had lung metastasis, 12 had liver metastasis, 3 brain metastasis, 2 bone metastasis, 2 subcutaneously metastasis and 1 post peritoneal lymphatic nodes. Thirty-six (80%) patients had ≥1 systemic regimen before radiotherapy, and 17 (37.8%) patients had ≥2 regimens. The diameter of irradiated lesions ranges from 1 to 5.5cm. The prescribed doses were 32 to 40 Gy in 4 to 5 fractions to the brain lesions, 48 to 64 Gy in 6 to 8 fractions to the lung or liver lesions, 32 to 60 Gy in 4 to 10 fractions in other lesions, with modification according to the tolerance of the adjacent normal tissue. Biologically effective dose (BED) ranges from 57 to 132 Gy with a median of 86.4 Gy. The median follow-up period was 8 months (range, 2-21months). The 12-month and 18-month local control rates were 84.2% and 76.5%, respectively. In subgroups, the 12-month local control rates for BED ˂100 Gy and ≥100 Gy were 75% and 85% respectively. Local recurrence occurred in 5 patients (11.1%), among which 3 had KRAS mutant disease and 2 were of unknown KRAS status. Univariate analysis showed that there was no significant difference in local control rate based on BED value (˂100 Gy versus ≥100 Gy), KRAS status (mutant versus wild type) or metastatic tumor site (lung versus liver). The 6-month and 12-month PFS rate were 53.7% and 15.1% respectively and the median PFS was 7 months. There were no grade 3 or higher toxicities. Eight patients developed grade 2 acute toxicities including fatigue, cough and diarrhea; two patients developed grade 2 late toxicities including chronic cough and abdominal pain. This study showed that stereotactic ablative radiotherapy is well tolerated and effective for colorectal oligometastases. A prescription dose of BED ≥100 Gy should be considered if normal tissue constraints allow. Correlation of disease and treatment characteristics with local control needed to be investigated with larger cohort. Further homogenous cohort would better evaluate long term benefit of stereotactic ablative radiotherapy for patients with oligometastatic CRC.

Local-Regional Therapy for Oligometastatic Colorectal Cancer

Local Therapy for Metastatic Colorectal Cancer

Local Therapy for Metastatic Colorectal Cancer: A Case-Based Review

Local and Systemic Therapies for Liver Metastases

Current evidence on local therapy in oligometastatic prostate cancer

Oligometastasis: Expansion of Curative Treatments in the Field of Oncology

Treatment Strategies for Oligometastatic Breast Cancer

Immunotherapy Combined with Local Therapy in the Late-Line Treatment of Repair-Proficient (pmmr)/microsatellite Stable (MSS) Metastatic Colorectal Cancer

Treatment of Locally Advanced/Metastatic Colorectal Cancer

Current treatment for liver metastases from colorectal cancer.

Locoregional therapy for oligometastatic cervical cancer: a single-center retrospective study

Current Treatment for Liver Metastases from Colorectal Cancer

Locoregional Therapies for Primary and Metastatic Breast Cancer: AJR Expert Panel Narrative Review

Applications of image-guided locoregional transarterial chemotherapy in patients with inoperable colorectal cancer: a review

Efficacy and Safety Outcomes of Using Stereotactic Ablative Radiotherapy for Oligometastatic Lesions from Colorectal Cancer

Local Therapy Improves Survival for Early Recurrence After Resection of Colorectal Liver Metastases

[Interventional therapy of colorectal liver metastasis]

Management of Liver Oligometastatic Esophageal Cancer: Overview and Critical Analysis of the Different Loco-Regional Treatments

Imaging Considerations before and after Liver-Directed Locoregional Treatments for Metastatic Colorectal Cancer

Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma

Locally ablative treatment of breast cancer liver metastases: identification of factors influencing survival (the Mammary Cancer Microtherapy and Interventional Approaches (MAMMA MIA) study)